Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Severe asthma with blood hypereosinophilia associated with JAK2 V617F mutation: a case series

Laure Tabèze, Sylvain Marchand-Adam, Raphaël Borie, Aurélien Justet, Clairelyne Dupin, Marie-Christine Dombret, Bruno Crestani, Camille Taillé
European Respiratory Journal 2019 53: 1802248; DOI: 10.1183/13993003.02248-2018
Laure Tabèze
1Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvain Marchand-Adam
2Département de Pneumologie et Explorations fonctionnelles respiratoires, Centre Hopitalo Universitaire de Tours, Tours, France
3INSERM U-1100, Faculté de médecine, Université François Rabelais, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raphaël Borie
1Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raphaël Borie
Aurélien Justet
1Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clairelyne Dupin
1Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Christine Dombret
1Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Crestani
1Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camille Taillé
1Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Hypereosinophilia (blood eosinophil count >1500 per mm3) in asthma patients may hide some rare myeloid or lymphoid neoplasms. Their identification has prognostic and therapeutic relevance because of the potential for targeted therapy. http://bit.ly/2JCoVIA

To the Editor:

In a large subset of patients with asthma, blood eosinophilia is common, as a marker of T-helper type 2 cell (Th2) inflammation. Hypereosinophilia (HE), defined by blood eosinophil count >1500 per mm3, is rare, observed in 0.3% of asthmatic patients [1]. Classically, in the context of uncontrolled asthma and HE, allergic bronchopulmonary aspergillosis, vasculitis or parasitic infection must be investigated [2]. Asthma is also a feature of HE related to various haematological disorders, although respiratory manifestations are rarely isolated in this setting [2].

Between 2009 and 2018, among 1200 patients evaluated in our reference centre for severe asthma in Bichat Hospital, 34 (3%) had blood eosinophil count >1500 per mm3 on at least two tests. All patients with recurrent HE were asked to undergo a diagnostic work-up including vitamin B12 and tryptase dosage, blood smear examination and screening for the fusion genes FIPL1-PDGFRA (FIP1-like 1–platelet-derived growth factor receptor-α) and ETV6-PDGFRB (ETS variant 6–platelet-derived growth factor receptor-β), Janus kinase 2 (JAK2) point mutation, and blood T-cell clone [3, 4]. Bone-marrow analysis was performed when features of lympho- or myeloproliferative disorders were found.

We identified three patients (two females), aged 38 to 65 years, with a JAK2 (V617F) mutation, approximately 9% of the 34 patients with severe asthma and HE. One patient also had a T-cell clone (patient 2). All had early-onset atopic asthma, with loss of control during adulthood (table 1). HE appeared at age 17, 45 and 55 years, with maximum blood eosinophil count 5540, 4510 and 2000 per mm3, respectively. For all, previous chest computed tomography imaging had revealed transient pulmonary infiltrates, with evidence of eosinophilic alveolitis on bronchoalveolar lavage in two patients. Two patients had a history of venous or arterial thrombosis requiring long-term anticoagulation. A systematic search for vasculitis or aspergillus sensitisation was negative in all patients. In one patient (patient 1), the platelet count was above normal at the time of evaluation, and bone marrow biopsy confirmed a myeloproliferative disorder, which was treated with hydroxyurea. Patient 2 showed high circulating level of B12 vitamin, but normal level of tryptase and bone marrow examination was normal. Patient 3 had no features of a myeloid neoplasm but had venous thromboembolism a few months before the JAK2 mutation finding. For all patients, loss of asthma control appeared less than 1 year before the diagnosis of the JAK2 point mutation. Patients 2 and 3, routinely followed for at least 3 years, currently require low dose prednisone for control of asthma, with normal eosinophil and platelet counts.

View this table:
  • View inline
  • View popup
TABLE 1

Clinical characteristics of three patients with asthma and hypereosinophilia

JAK2 is a receptor-associated tyrosine kinase activated by several cytokines and growth factors [4]. In eosinophils, JAK2 is phosphorylated and activated after stimulation of the interleukin-5 receptor by the ligand and plays a major role in regulating eosinophilic development [4], migration and activation [5]. It is also involved in inhibiting apoptosis induced by granulocyte-macrophage colony-stimulating factor. A JAK2 gene polymorphism was found associated with increased frequency of virus-induced asthma exacerbations and increased susceptibility to allergic sensitisation to environmental antigens [6]. In murine asthma models, JAK inhibitors inhibit Th2 differentiation, reduce allergen-induced airway eosinophilia, and prevent airway hyper-responsiveness, mucus hypersecretion and Th2 cytokine production [7, 8].

The JAK2 mutation p.Val617Phe (V617F) induces a constitutively active protein and leads to myeloproliferation. The JAK2 V617F point mutation is found in 27% of cases of chronic myeloproliferative disorder [9], mainly polycythemia vera (PV) cancer and essential thrombocythemia (ET). HE may be observed in some cases of PV and ET, with higher values observed in JAK2 V617F-positive than -negative cases [9, 10], with the increase in granulocyte count depending on allele burden. JAK2 mutation is also detected in 1.5% to 4% of patients with HE of unknown significance, and is associated with a poor prognosis [9, 10].

All patients in our series had childhood asthma, but loss of control appeared later, simultaneously with HE and JAK2 mutation diagnosis. We cannot exclude an incidental finding, especially in patient 3, who currently has no features of haematological neoplasm and may have a low allele burden, which was not assessed. However, given the known role of JAK2 in eosinophil activation and asthma pathophysiology [7, 8], we consider that JAK2 mutation, at least in our patients, may contribute to increased blood eosinophilia count and therefore asthma severity.

In our centre, we did not find any other haematological neoplasm associated with HE, probably because of recruitment bias, since haematological disorders with HE are rarely associated with localised disease such as asthma or eosinophilic pulmonary infiltrates at disease onset. For example, in a small series of 18 asthma patients with HE, only one had a clonal T-cell receptor-gamma rearrangement [11]. One case of severe asthma in a child revealing a lymphoid variant of HE syndrome has been reported [12].

Our case series, with the limitation of bias due to its retrospective design, emphasises that HE in severe asthma patients may hide some rare haematological neoplasms, with lung manifestations as a single organ involvement. Blood eosinophilia >2000 per mm3, pulmonary infiltrates, persistence of high blood eosinophil counts under oral steroids, history of venous or arterial thrombosis, or increased platelet count should signal a possible haematological neoplasm and trigger a thorough evaluation.

This evaluation seems important because in patients with severe asthma, new biological therapies targeting the Th2 response specifically target disease with increased blood eosinophil count [13]. Mepolizumab has demonstrated clinical benefit in conditions with high eosinophil count other than asthma, such as HE syndrome [14] and eosinophilic granulomatosis with polyangiitis [15]. Despite the rarity of those molecular aberrations, their identification has prognostic and therapeutic relevance because of the potential for targeted therapy with JAK inhibitors [5, 7]. In patients with severe asthma and recurrent HE, screening for lympho- or myeloproliferative disorders (at least blood smear examination, tryptase and vitamin B12 dosage [3]) should be part of the evaluation.

Footnotes

  • Conflict of interest: L. Tabèze has nothing to disclose.

  • Conflict of interest: S. Marchand-Adam has nothing to disclose.

  • Conflict of interest: R. Borie reports grants and personal fees from Boehringer Ingelheim and Roche, outside the submitted work.

  • Conflict of interest: A. Justet has nothing to disclose.

  • Conflict of interest: C. Dupin has nothing to disclose.

  • Conflict of interest: M-C. Dombret has nothing to disclose.

  • Conflict of interest: B. Crestani reports research and travel grants and personal fees for lecturing from Boehringer Ingelheim and Roche, travel grants from Apellis, personal fees for travel and lecturing from AstraZeneca and Sanofi, grants from Medimmune, outside the submitted work.

  • Conflict of interest: C. Taillé reports personal fees from and acting as study investigator for AstraZeneca, Boehringer, Novartis and ALK, personal fees from Chiesi and Teva, grants and personal fees from and acting as study investigator for GSK, acting as study investigator for Sanofi, outside the submitted work.

  • Received November 29, 2019.
  • Accepted March 3, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Price DB,
    2. Rigazio A,
    3. Campbell JD, et al.
    Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015; 3: 849–858.
    OpenUrl
  2. ↵
    1. Weissler JC
    . Eosinophilic lung disease. Am J Med Sci 2017; 354: 339–349.
    OpenUrl
  3. ↵
    1. Groh M,
    2. Pagnoux C,
    3. Baldini C, et al.
    Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015; 26: 545–553.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Watanabe S,
    2. Arai Ki
    . Roles of the JAKSTAT system in signal transduction via cytokine receptors. Curr Opin Genet Dev 1996; 6: 587–596.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Monahan J,
    2. Siegel N,
    3. Keith R, et al.
    Attenuation of IL-5-mediated signal transduction, eosinophil survival, and inflammatory mediator release by a soluble human IL-5 receptor. J Immunol 1997; 159: 4024–4034.
    OpenUrlAbstract
  6. ↵
    1. Tripathi P,
    2. Hong X,
    3. Caruso D, et al.
    Genetic determinants in the development of sensitization to environmental allergens in early childhood. Immun Inflamm Dis 2014; 2: 193–204.
    OpenUrl
  7. ↵
    1. Kudlacz E,
    2. Conklyn M,
    3. Andresen C, et al.
    The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 2008; 582: 154–161.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ashino S,
    2. Takeda K,
    3. Li H, et al.
    Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses. J Allergy Clin Immunol 2014; 133: 1162–1174.e4.
    OpenUrl
  9. ↵
    1. Jones AV,
    2. Kreil S,
    3. Zoi K, et al.
    Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Schwaab J,
    2. Umbach R,
    3. Metzgeroth G, et al.
    KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance. Am J Hematol 2015; 90: 774–777.
    OpenUrl
  11. ↵
    1. Freymond N,
    2. Kahn J-E,
    3. Legrand F, et al.
    Clonal expansion of T cells in patients with eosinophilic lung disease. Allergy 2011; 66: 1506–1508.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Leu T,
    2. Rauthe S,
    3. Wirth C, et al.
    Ein T-Zell assoziiertes Hypereosinophilie-Syndrom (L-HES) als Differenzialdiagnose eines Asthma bronchiale [The lymphoid variant of HES (L-HES) as differential diagnose of severe asthma in childhood]. Klin Padiatr 2016; 228: 319–324.
    OpenUrl
  13. ↵
    1. Israel E,
    2. Reddel HK
    . Severe and difficult-to-treat asthma in adults. N Engl J Med 2017; 377: 965–976.
    OpenUrlCrossRef
  14. ↵
    1. Kuang FL,
    2. Fay MP,
    3. Ware J, et al.
    Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome. J Allergy Clin Immunol Pract 2018; 6: 1518–1527.
    OpenUrl
  15. ↵
    1. Wechsler ME,
    2. Akuthota P,
    3. Jayne D, et al.
    Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 2017; 376: 1921–1932.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 53 Issue 6 Table of Contents
European Respiratory Journal: 53 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Severe asthma with blood hypereosinophilia associated with JAK2 V617F mutation: a case series
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Severe asthma with blood hypereosinophilia associated with JAK2 V617F mutation: a case series
Laure Tabèze, Sylvain Marchand-Adam, Raphaël Borie, Aurélien Justet, Clairelyne Dupin, Marie-Christine Dombret, Bruno Crestani, Camille Taillé
European Respiratory Journal Jun 2019, 53 (6) 1802248; DOI: 10.1183/13993003.02248-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Severe asthma with blood hypereosinophilia associated with JAK2 V617F mutation: a case series
Laure Tabèze, Sylvain Marchand-Adam, Raphaël Borie, Aurélien Justet, Clairelyne Dupin, Marie-Christine Dombret, Bruno Crestani, Camille Taillé
European Respiratory Journal Jun 2019, 53 (6) 1802248; DOI: 10.1183/13993003.02248-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Leukocyte telomere length and mycophenolate therapy in CHP
  • Connexins and the pulmonary vascular response to hypoxia
  • Fixed breathing protocols in multiple-breath washout testing in children
Show more Agora

Research letters

  • Leukocyte telomere length and mycophenolate therapy in CHP
  • Connexins and the pulmonary vascular response to hypoxia
  • Fixed breathing protocols in multiple-breath washout testing in children
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society